Luis Ines - Hospitais da Universidade de Coimbra

基本信息

浏览量：17

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 147 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

The “target Sign”: A Hallmark of Lupus Enteritis

Adriana C. Esteves,Beatriz Mendes,Helena Assunção,Luís Inês

Reumatología Clínicano. 9 (2024): 515-516

引用0浏览0WOS引用

P129 Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort

María Galindo,Luís Inês,Francisco Rubiño,Iñigo Rua Figueroa,Eva Tomero Muriel,Coral Mouriño Rodriguez,Esther Uriarte Isacelaya,Jose Maria Pego Reigosa,Irene Altabás González,Esther Rodriguez Almaraz,Inigo Hernandez Rodriguez,Raul Menor Almagro, Tarek Salman Montes,Irene Carrion Barbera,Norman Jimenez

Poster presentations (2024)

引用0浏览0引用

OMERACT Systemic Lupus Erythematosus Domain Survey

SEMINARS IN ARTHRITIS AND RHEUMATISM (2024)

引用1浏览0WOS引用

EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update

ANNALS OF THE RHEUMATIC DISEASESno. 1 (2024): 15-29

引用1007浏览0WOS引用

1007

O21 is SLE-DAS Better Than BILAG-2004 to Identify Severe SLE Disease Activity? Post-hoc Analysis of 438 SLE Patients from the Anifrolumab Clinical Trials

Andrea Doria,Diogo Jesus,Ana Matos,Carla Henriques,Luís Sousa Inês

Lupus Science and Medicine（2024）

引用0浏览0引用

P127 the SLE-DAS Enables Easy Identification of SLE Patients with Moderate-to-severe Disease Activity and Worse HR-QoL in the Screening for SLE Clinical Trials: a Post-Hoc Study in the Phase 2 and 3 Anifrolumab Trials

Andrea Doria,Diogo Jesus,Ana Matos,Carla Henriques,Luís Sousa Inês

Lupus Science and Medicine（2024）

引用0浏览0引用

Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug from Placebo and Better Health-Related Quality of Life

Diogo Jesus,Carla Henriques,Ana Matos,Andrea Doria,Luis S. Ines

ARTHRITIS CARE & RESEARCH（2024）

引用0浏览0WOS引用

POS0733 VALIDATION OF THE SLE-DAS RESPONDER INDEX AS AN ACCURATE AND FEASIBLE ENDPOINT FOR SLE CLINICAL TRIALS: A POST-HOC STUDY IN THE PHASE 2 AND 3 ANIFROLUMAB CLINICAL TRIALS

Jesus D.,Henriques C.,Matos A.,Doria A.,Inês L.

Annals of the Rheumatic Diseases (2024): 1004-1005

引用0浏览0引用

Risk of Chronic Kidney Disease in 260 Patients with Lupus Nephritis—analysis of a Nationwide Multicentre Cohort with Up to 35 Years of Follow-Up

Filipa Farinha,Sofia Barreira,Maura Couto,Margarida Cunha,Diogo Fonseca,Raquel Freitas,Luis Ines,Mariana Luis,Carla Macieira,Ana R. Prata,Joana Rodrigues,Bernardo Santos,Rita Torres,Ruth J. Pepper,Anisur Rahman,Maria J. Santos

RHEUMATOLOGY（2024）

引用0浏览0WOS引用

Anti-PTX3 Antibodies: Towards a New Concept of Pain in Rheumatoid Arthritis

Cátia Duarte,Luís S Inês

Rheumatology (Oxford, England) (2024)

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn